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Arrythmogenic right ventricular cardiomyopathy (ARVC) is a genetic form of 
cardiomyopathy causing fibro-fatty replacement of the myocardium. Although  
usually transmission is autosomal dominant, 12 genes encoding cardiac desmo-
somes have been found to be closely linked to this disease process shifting the 
congenital disease theory to a genetic one. The categorisation of ARVC as a myo-
cyte adhesion disorder was first suggested by a molecular genetic study involving 
patients with Naxos disease. Misnomeric to only affect the right ventricle, ARVC 
also affects the left ventricle - culminating into biventricular failure as a long term 
prognosis. Epidemiology is well established with a male to female preponderance. It 
is currently the second most common cause of sudden cardiac death (SCD) in popu-
lation < 35 yrs. Pathological basis of the varied clinical presentation is explained at 
the molecular level with myocardial atrophy, fibro-fatty replacement and chamber 
dilatation. Diagnosing the condition by ruling out the pitfall differentials is an 
enormous challenge due to the broad phenotypic spectrum including syncope on 
one end and SCD on the other. Task Force Criteria combines electrocardiography 
(ECG), echocardiography (ECHO), cardiac magnetic resonance imaging (CMRI), 
myocardial biopsy for diagnosis; early detection, family screening and risk strati-
fication being the cornerstones. Therapeutic options although limited due to the 
progressive nature of the disease is based on preventing life threatening arrhyth-
mias encompassing primary and secondary prevention - Implantable cardioverter 
-defibrillator (ICD) implantation, radiofrequency ablation and heart transplanta-
tion are the main ones.
Keywords: Arrythmogenic right ventricular cardiomyopathy (ARVC), 
Arrythmogenic right ventricular dysplasia (ARVD), sudden cardiac death, 
cardiomyopathy, genetic cardiomyopathy, cardiac desmosomes, plakophilin-2  
(PKP-2), pathophysiology, diagnosis, treatment
1. Introduction
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a 
genetic form of cardiomyopathy and was initially known to primarily affect only the 
right ventricle (RV). It has now been found out that this disease process also may 
involve the left ventricle (LV) and culminate in life-threatening ventricular arrhyth-
mias prompting sudden cardiac death (SCD) and/or biventricular heart failure [1]. 
ARVC is one of the leading causes of arrhythmic cardiac arrest in young people and 
athletes [2, 3]. The pathological hallmark of the disease is progressive loss of right 
ventricular myocardium and its replacement by fibrofatty tissue (Figure 1) [2, 4].
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2. Epidemiology
The estimated prevalence of ARVC in the general population is approximately 
1:5000 but in some European countries like Italy and Germany, it can be almost 
1:2000, affecting men more frequently than women with a ratio of 3:1 [2] and can 
be explained either by a direct influence of sex hormones on the mechanisims 
involved in the phenotypic expression of the disease [2] or by sex based differences 
in the amount or intensity of exercise [2].
The exact prevalence, however, is unknown and could be higher than the esti-
mated value because of the existence of many undiagnosed or missed diagnosed cases.
Approximately 50% of affected patients have a positive family history, but both 
incomplete penetrance and limited phenotypic expression are common and proba-
bly account for underestimation of the prevalence of familial disease. The disease is 
typically transmitted with an autosomal dominant pattern of inheritance, although 
rare autosomal recessive forms have been described [3].
3. History
This disease was first described in 1736 by the Pope’s physician, Giovanni Maria 
Lancisi in his book De Motu Cordis et Aneurysmatibus where he mentions about a 
family where the affected members of the family had presented with palpitations, 
heart failure dilation and aneurysms of RV and SCD [4].
Dalla Volta et al. Reported a patient having “auricularization” the RV pressure 
curve, in 1961, emphasising on the peculiar haemodynamic picture of this non-
ischaemic heart muscle disease where the RV was behaving like an atrium [5]. It was 
only in the 1980’s when Drs Marcus, Nava, and Thiene found out the first clinical 
and pathologic series of patients with ARVC [6].
Figure 1. 
Heart of a 37-year-old woman admitted with heart failure who suffered a subsequent cardiac arrest. The arrow 
identifies fatty infiltration of the right ventricle [9].
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In 1982, Marcus et al. reported the disease in 24 adults, emphasising the origin 
of arrhythmias from the RV and the histopathological substrate consisting of 
fibrofatty replacement of the RV free wall. He also accounted for the ventricular 
arrhythmias of RV origin with left bundle branch block (LBBB) morphology. 
However, it was not until 1984 that the electrocardiographic features of ARVC were 
first elaborately described including the epsilon wave [6].
In 1988, Thiene et al. mentioned a significant series of sudden deaths in the 
young (< 35 years). It was noted that the pathology consisting of ARVC mostly 
occurred during effort and were characterised by ventricular arrhythmias of LBBB 
morphology and inverted T- waves in the right precordial leads in electrocardio-
gram (ECG). At the time this accounted for 20% of all sudden deaths in the young 
and this was the first time when ARVC was acknowledged as an important cause of 
sudden deaths in the young population [6].
ARVD1 is the first gene locus that was found by Rampazzo et al. in 1994 at chro-
mosome 14q23 [5]. Basso et al. described the pathological profile in detail in 1996. 
He emphasised the frequent left ventricular (LV) involvement and the presence of 
an inflammatory component [6].
ARVC was included among cardiomyopathies in the revised World Health 
Organisation (WHO) classification in 1995 and progressive cell death (apoptosis) in 
myocyte was proven [6].
The need of an International Registry of the disease arose and two research 
programs where implemented on both sides of the Atlantic Ocean [6].
The first gene defect was discovered in the recessive variant of the disease which 
was originally identified in 1985 from the Naxos island and consisted of a cardiocu-
taneous syndrome presenting with ARVC, palmoplantar keratosis and woolly hair. 
A deletion was detected in the gene encoding plakoglobin which is the cell function 
protein [6].
Thereafter, other genes which encode cell junction proteins were found defective 
in the dominant, classical form of ARVC. Some of them were desmoplakin, pla-
kophilin, desmoglein-2, desmocollin-2. These mutations accounted for intercalated 
disc remodelling at the ultrastructural level. The other variants of the disease were 
explained by mutation of ryanodine- 2 receptor and transforming growth factor 
beta 3 gene [6].
4. Genetics
ARVC is typically inherited as a dominant Mendelian disease, although 
recessive variants exist and the involvement of family members often can only be 
detected by directed screening. Human genetic studies in the past have offered 
insight into the potential causes of ARVC. Early work demonstrated substantial 
genetic heterogenetic T cells, and at least 9 independent loci have now been 
identified [7].
The genetic hypothesis has been thoroughly studied. The first chromosomal 
locus identified was published by Rampazzo [8] et al. in 1994 in Italy as previously 
mentioned. Linkage analysis supported the evidence for genetic heterogeneity 
for several ARVC loci on chromosomes (1, 2,3,6,10,12 and 14) [1, 8]. Similarly, he 
reported the desmoplakin gene (DSP), the first desmosomal protein gene to be 
associated with a major form of the disease, with autosomal dominant inheritance, 
also called ARVC type 8 [1].
In addition, the gene for Naxos disease was mapped on chromosome 17 (locus 
17q21), by McCoy et al. [1]. This is the first disease causing gene, also named junc-
tion plakoglobin (JUP) gene (autosomal recessive variant of ARVC) [1].
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The discovery of cutaneous and hair follicle involvement in recessive forms of 
ARVC led to the identification of mutations in the desmosomal proteins plakoglo-
bin and desmoplakin [7]. These findings also implicated other desmosomal proteins 
or their partner proteins as candidate causes of the disorder. Subsequent work has 
revealed desmosomal mutations in a small proportion of dominantly inherited 
ARVC cases and in arrhythmogenic cardiomyopathy localised to the left ventricle 
[7]. The description of mutations in the cardiac ryanodine receptor in families 
with an exercise-related arrhythmia known as catecholaminergic, a polymorphic 
ventricular tachycardia has highlighted phenotypic distinctions from typical ARVC 
[7]. ARVC genetics took a significant step forward when it was discovered that 
mice null for the Armadillo protein plakophilin 2 (PKP 2), another desmosomal 
component, die at around E 11 with profound cardiac abnormalities [7]. These mice 
fail to form normal cardiac desmosomes, and desmoplakin disassociates from the 
abnormal junctions accumulating in cytoplasmic aggregates. These findings led in 
turn to the discovery of dominant mutations in the PKP2 gene in a large proportion 
of probands with ARVC and not only established mutant desmosomal proteins 
as a major cause of the syndrome but also raise the possibility of genetic testing 
as a diagnostic tool [7]. The initial report in a series of 120 and selected European 
probands identified PKP2 mutations in almost 1/3 of these individuals. Data from 
more selected cohorts of index patients with evidence of familial involvement have 
suggested that as many as 70% of such kindreds may have mutations in PKP2. Of 
note, these investigators also described evidence of founder effects for several PKP2 
to mutations in remote kindreds, implying less dramatic effects on survival than are 
seen in other forms of ARVC [7].
A recessive mutation of DSP has been reported and associated with Carvajal 
syndrome, another cardiocutaneous disease [1]. PKP2 is the most frequent targeted 
protein with more than 25 different mutations identified in the gene encoding it. 
Thus, ARVC was found to be mainly a disease of the cardiomyocyte junction [2].
Furthermore, extra-desmosomal gene, unrelated to the cell adhesion complex, 
have been implicated as autosomal dominant forms of ARVC, such as (1). the 
cardiac ryanodine-2 receptor gene, responsible for the release of calcium from 
the sarcoplasmic reticulum; (2). the transforming growth factor beta3 gene (TGF 
beta3) implicated in the regulation of production of extracellular matrix and 
expression of genes encoding desmosomal proteins and the TMEM43 genes [1].
The cardiac ryanodine receptor gene (RyR2) has also recently been implicated 
in ARVC and office potential insight into the Association of Edren it adrenergically 
mediated ventricular arrhythmias with this disease. The ryanodine receptor induces 
calcium released from the sarcoplasmic reticulum into the cytosol. The cardiac 
ryanodine receptor has also been identified as being responsible for catecholamine-
induced ventricular tachycardia. Its skeletal muscle counterpart has been implicated 
in malignant hyperthermia and central core disease, a congenital myopathy but the 
mechanisms by which mutations in the cardiac ryanodine receptor might mediate 
fibrofatty myocardial changes are not clear and will likely be the focus of future 
studies [9].
The discovery of these gene mutations allowed preliminary genotype– 
phenotype correlations to be made.
5. Histopathology
Characteristically, the RV in ARVC is replaced with a fibrofatty tissue. 
Morphologic alterations of ARVC usually begin in the subepicardium or 
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mediomural layers of the RV and progress to the endocardium with fibrofatty 
replacement of myocytes and thinning of the wall (Figure 2). The regions of RV 
most frequently involved are the RV inflow area, the apex and the infundibulum. 
These three areas form “the triangle of dysplasia” [9]. However, small amounts of 
fat are present in the epicardial layer and within the RV myocardium in normal 
subjects. Fontaine et al. examined the hearts at necropsy in 140 individuals with 
no history of heart disorders. Over 50% of the subjects had fat within their RV 
myocardial fibres, and the presence of intramyocardial fat increased with age. 
Therefore, histologic diagnosis of ARVC may be difficult in borderline cases. To 
avoid overdiagnosing ARVC, Angeline et al. have proposed that the presence in 
biopsy sections of more than 3% of fibrous tissue and more than 40% of fatty 
tissue is highly suggestive of ARVC. These authors also emphasised the impor-
tance of identifying coexisting myocardial fibrosis in making the diagnosis. In 
a forensic autopsy study of 20 patients with ARVC who died suddenly, the fatty 
replacement involved the outer half of the RV free wall in 27%, the other 2/3 
in 28% and the entire wall thickness in 45% of the cases [9]. Interestingly, the 
endocardial muscular trabeculae are generally spared but may occasionally also 
be atrophied. The LV was involved in 40% of cases in this report, although other 
reports have the identified LV involvement in up to 76% of individuals with 
ARVC examined at necropsy. When the LV is involved, the fibrofatty replace-
ment can affect both the septum and LV free wall, either diffusely or, more often, 
regionally with a predilection for the posteroseptal and posterolateral areas. In 
the LV, fatty replacement of the myocardium has a predilection for the subepicar-
dial and midventricular wall [9].
Figure 2. 
Typical histologic features of ARVC/D. ongoing myocyte death (a) with early fibrosis and adipocytes 
infiltration (b) [6].
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6. Pathogenesis
ARVC was initially believed to be secondary to a developmental defect of the 
RV myocardium, leading to the original designation of “dysplasia”, similar to 
Uhl’s anomaly [1]. Nonetheless, this process differs from ARVC/D based on the 
fact that Uhl’s anomaly has not been documented to have a genetic basis, and it 
is not recognised as a desmosomal disease. In addition, myocardial atrophy is the 
consequence of cell death after birth and its progressive postnatal development has 
been definitely assessed. This concept has evolved over the last 30 years and based 
on its clinical characteristics, pathophysiology, postnatal development and genetic 
background, its inclusion in the World Health Organisation (WHO) classification 
of cardiomyopathies was finally achieved [1].
Several studies have been performed to determine the aetiology and pathogen-
esis of ARVC. However, there is still conflicting evidence. Different courses have 
been suggested as congenital defects, genetics and acquired factors [1]. In approxi-
mately 30–50% of cases it is transmitted with an autosomal dominant pattern of 
inheritance, with incomplete penetrance and variable expression [1].
Acquired factors have also been suggested as the cause of ARVC. The strongest 
association has been made with viral myocarditis inducing arrhythmogenic car-
diomyopathy due to histopathological similarity between the two of lymphocytic 
infiltrate with disappearance of myocytes and fibrofatty replacement [1].
How do the mutant junctional proteins result in a unique, predominantly right 
ventricular cardiac phenotype? Desmosomal proteins are widely expressed, so the 
focal nature of apparent pathology in both dominant and recessive ARVC led to 
initial speculation on the role of mechanical stresses. Impaired desmosome function 
under conditions of mechanical stress was proposed to predispose to cardiomyocyte 
detachment and death, with subsequent inflammatory reaction and fibrofatty 
replacement. However, consideration of the distribution of skin lesions in recessive 
variants infers that this mechanism alone is unlikely to be responsible. Several areas 
of the body subject to substantial physical stresses are not involved, while the hair 
follicles are uniformly affected. In addition, the prominent adipose replacement 
suggests not scarring and healing, but rather a more fundamental perturbation of 
primary tissue architecture [7].
Three different types of intercellular junction are distinguished at the cardiac 
intercalated disc: (a) adherens junctions, which anchor actin filaments; (b) des-
mosomes, which anchor intermediate filaments; and (c) gap junctions, which 
mediate ion transfer. Cardiac myocytes rely on these specialised structures for both 
mechanical and electrical coupling of the myocardial syncytium [7]. Desmosomes 
may protect other junctions from mechanical stress, but they also have been impli-
cated in the structural organisation of the intercalated disc. Desmosome dependent 
orchestration of local membrane and cytoplasmic domains may be critical for many 
of the physiologic functions of the intercalated disc. For example, the destabilisa-
tion of cell adhesion complexes may perturb the kinetics of gap junction turnover, 
resulting in heterogeneous conduction, a potential contributor to arrhythmogenesis 
in ARVC [7].
Desmosomes also participate in intercellular signalling networks, of which 
the Wnt/beta-catenin pathway is the most extensively studied. In the archetypal 
pathway the cytoplasmic concentration of beta-catenin is exquisitely regulated by 
multiple inputs, including secreted ligands of the Wnt family and recruitment of 
beta-catenin to intercellular junctional complexes. Cytoplasmic accumulation of 
beta-catenin leads to its nuclear translocation, association with the T-cell factor/
lymphoid enhancer factor (Tcf/Lef) family of transcription factors and subsequent 
changes in gene expression. This evolutionarily conserved pathway plays a central 
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role in many of the most fundamental cellular behaviours and has been directly 
implicated in the regulation of cell fate, proliferation, and apoptosis. Importantly, 
the various pathway components are duplicated in higher organisms, and specific 
isoforms may even be employed serially for discrete functions at different times and 
at different sites. In addition, superimposed on the basic structure of the Wnt/beta-
catenin signalling network are many subtle feedback loops and points of cross-talk 
that are only beginning to be uncovered [7].
Elegant immunohistochemical studies have shown that the mutant form of the 
plakoglobin protein fails to integrate into desmosomes and shifts from intercalated 
discs to site cytosol and nuclear pools, where it causes changes in nuclear signalling 
and the transcriptional activity, in particular through pathways regulated by the 
protein beta-catenin [2].
The fibrofatty tissue that replaces myocardium in ARVC is thought to contribute 
to the development of ventricular arrhythmias by slowing intraventricular conduc-
tion and acting as a substrate for arrhythmias through a scar related macroreentry 
mechanism, similar to that observed after myocardial infarction. Life-threatening 
ventricular arrhythmias in ARVC may also be the result of mechanisms operating at 
the molecular and cellular levels. Desmosomes, sodium channels, and gap junction 
proteins interact synergistically to regulate adhesion, excitability, and coupling of 
myocytes; this coordinated network of proteins located at the intercalated discs 
has been termed the “connexome” [2]. Loss of expression of desmosomal proteins 
may cause (or contribute to) potentially fatal arrhythmias by inducing gap junction 
remodelling, with reduction of total content and substantial redistribution of the 
gap-junction protein connexin 43, and decreasing the amplitude and kinetics of the 
sodium current [2].
The Brugada syndrome is a cardiac ion-channel disorder caused by a genetic 
deficiency in sodium channel function. There is some evidence that the Bruguda 
syndrome and ARVC may share clinical features and arrhythmic mechanisms as a 
result of their common origin from the connexome [2].
7. Clinical presentation
The onset occurs usually after childhood, with palpitations and/or syncope. The 
following clinical pictures have been observed [6]: 1. Subclinical face with con-
cealed structural abnormalities-the affected patient has no symptoms, and cardiac 
arrest may be the first and last manifestation of the disease. ARVC has been reported 
as one of the leading causes of sudden death in the young [6]. 2. Overt electrical 
disorder-with palpitations and syncope. The most typical clinical presentation of 
the disease is symptomatic ventricular arrhythmias of RV origin, usually triggered 
by effort. Arrhythmias range from isolated premature ventricular beat to sustained 
ventricular tachycardia (VT) with LBBB morphology up to ventricular fibrillation 
leading to cardiac arrest. The QRS morphology and axis during VT reflect its site 
of origin. A LBBB with inferior axis suggests an origin from the RV outflow tract 
(RVOT), while a LBBB with superior axis suggests an origin from the RV inferior 
wall. However, VTs with LBBB morphology are not specific for ARVC. Basal ECG 
may disclose inverted T waves in the right precordial leads (a T wave inverted beyond 
V1 after 14 years of age is almost pathognomonic of ARVC/D) (Figure 3) [6]. 
QRS enlargement of more than 110 ms and epsilon waves are strongly indicated of 
intraventricular impulse conduction delay. Signal average ECG may help to disclose 
fragmented low amplitude late potentials at the end of the QRS complex [6].
3. Heart failure- The progressive loss of the RV myocardium may impair the 
mechanical function of the RV and account for severe pump failure [6].  
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4. Biventricular failure- When the disease involves the ventricular septum 
and the LV, congestive heart failure occurs, mimicking dilated cardiomyopathy. 
Endocavitary mural thrombosis may occur, especially within aneurysms or in the 
atrial appendages when heart failure is complicated by atrial fibrillation, as to 
account for thromboembolism. In such conditions, contractile dysfunction may be 
so severe as to require cardiac transplantation. Clearly, when LV is affected ven-
tricular arrhythmias may appear polymorphic, originating from different cardiac 
regions. The occurrence of fatal outcome, mostly sudden death varies between 
0.1–3% per year in adults with diagnosed and treated ARVC, but it is unknown and 
may be higher in adolescents and young adults, in whom the disease is concealed 
and the first manifestation can be sudden death [6].
8. Diagnosis
To standardise the clinical diagnosis of ARVC, in 1994 an international task 
force proposed guidelines in the form of a qualitative scoring system with major 
and minor criteria [2]. In 2010, the task force revised the guidelines to improve 
diagnostic sensitivity, mostly for the clinical screening of family members, by 
providing quantitative criteria for diagnosing right ventricular abnormalities and 
adding molecular genetic criteria [1] (Table 1). However, the diagnosis remains 
problematic because of the low specificity of electrocardiographic abnormalities, 
multiple causes of right ventricular arrhythmias, difficulties in the use of imaging to 
assess right ventricular structure and function, and the sometimes puzzling results 
of genetic testing.
The diagnosis is particularly challenging in children, because clinical manifesta-
tions of earlier ARVC are subtle [2]. Cardiac Magnetic Resonance Imaging (MRI) 
is an attractive imaging toolBecause it is non-invasive and has the ability to charac-
terise tissue by distinguishing fat from muscle [6] (Figure 4) and has proved to be 
more sensitive than electrocardiography for detecting early ventricular dilatation 
and dysfunction in children [2].
Figure 3. 
A 17 year old asymptomatic male athlete who died suddenly during a soccer game. 12 lead ECG showing 
inverted T waves up to V4 (a) and isolated premature ventricular beats (b). In vitro MRI (c) and 
corresponding cross section of the heart (d) show RV dilatation with anterior and posterior aneurysms [6].
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I. Global or regional dysfunction/structural alterations
Major 2D TTE
Regional RV akinesia, dyskinesia or aneurysm
and 1 of the following criteria (end diastole):
• PLAX RVOT ≥32 mm (PLAX/BSA] ≥19 mm/m2)
• PSAX RVOT ≥36 mm (PSAX/BSA] ≥21 mm/m2)
or RV fractional area change ≤33 %
CMR
Regional RV akinesia, dyskinesia, or dyssynchronous RV 
contraction
and 1 of the following criteria (end diastole):
• RV end-diastolic volume /BSA ≥110 mL/m2 (male) or 
≥100 mL/m2 (female)
or RV ejection fraction ≤40 %
RV Angiography
Regional RV akinesia, dyskinesia or aneurysm
Minor 2D TTE
Regional RV akinesia, or dyskinesia
and 1 of the following criteria (end diastole):
• PLAX RVOT ≥29–31 mm ([PLAX/BSA] ≥16–18 mm/m2)
• PSAX RVOT ≥32–35 mm ([PSAX/BSA] ≥18–20 mm/m2)
• RV fractional area change >33–39 %
CMR
Regional RV akinesia, dyskinesia or dyssynchronous RV 
contraction
and 1 of the following criteria (end diastolic):
• RV end-diastolic volume/BSA ≥100–109 mL/'m2 (male) 
or ≥90–99 mL/m2 (female)
or RV ejection fraction >40–44 %
II. Histopathology (endomyocardial biopsy)
Major Residual myocytes <60 % by morphometric analysis (or <50 
% if estimated), with fibrous replacement of the RV free 
wall myocardium
≥1 sample, with or without fatty replacement
Minor Residual myocytes 60–75 % by morphometric analysis (or 
50–65 % if estimated), with fibrous replacement of the RV 
free wall
≥1 sample, with or without fatty replacement
III. Repolarisation abnormalities (14 years of age)
Major T-wave inversions V1–3 or beyond (in absence of complete 
RBBB)
Minor T-wave inversions V1–2 or V4–6 (in absence of complete 
RBBB)
T-wave inversions VI–4, if complete RBBB present
IV. Depolarisation abnormalities
Cardiomyopathy - Disease of the Heart Muscle
10
Figure 4. 
MRI in a patient affected by ARVC/D (long axis view of the right ventricle): Note the transmural 
diffuse bright signal in the RV free wall on spin echo T1 (a) due to massive myocardial atrophy with fatty 
replacement (b) [6].
Major ε wave (reproducible low-amplitude signals between end of 
QRS complex to onset of the T wave) in V1–3
Minor Signal-averaged ECG with late potentials (if QRS on 
standard surface ECG <110 ms)
V. Arrhythmias
Major Non-sustained or sustained ventricular tachycardia (VT) of 
LBBB morphology with superior axis
Minor Non-sustained or sustained VT of RVOT configuration, 
LBBB morphology with inferior axis or of unknown axis
>500 VES per 24 h (Holter)
VI. Family history
Major ARVC/D in a first-degree relative who meets current Task 
Force Criteria
ARVC/D confirmed pathologically at autopsy or surgery in a 
first-degree relative
Identification of a pathogenic mutation categorised as 
associated with ARVC/D in index patient
Minor Suspected ARVC/D in a first-degree relative (current Task 
Force criteria can not be determined)
Premature SCD (<35 years of age) due to suspected ARVC/D 
in a first-degree relative
ARVC/D confirmed pathologically or by current Task Force 
Criteria in second-degree relatives
Definite diagnosis: two major or one major and two minor criteria or four minor from different categories; 
Borderline diagnosis: one major and one minor or three minor criteria from different categories; Possible diagnosis: 
one major or two minor criteria from different categories BSA - body surface area; CMR - cardiac magnetic 
resonance tomography; ECG - electrocardiogram; LV - left ventricle; PLAX - parasternal long-axis view; PSAX -  
parasternal short-axis view; RBBB - right bundle branch block; RVOT - RV outflow tract;
RV - right ventricle; TTE - transthoracic echocardiogram; VES - ventricular extrasystole; VT - ventricular 
tachycardia.102
Table 1. 
Revised 2010 task force criteria for diagnosis of ARVC/D [1].
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Conditions that may be difficult to differentiate from ARVC include idiopathic 
right ventricular outflow-tract tachycardia, cardiac sarcoidosis, and continental 
heart disease leading to right ventricular volume overload. Biventricular variants of 
the disease with severe left ventricular involvement may be indistinguishable from 
dilated cardiomyopathy. The difficult differential diagnosis, together with referral 
bias, may account for the discrepancies in the reported incidence of heart failure in 
patients with ARVC [2].
9. Risk stratification
The clinical course of ARVC is characterised by the occurrence of arrhyth-
mic events, which can cause SCD, and the impairment of biventricular systolic 
function, which can lead to death from heart failure. The estimated overall 
mortality varies among studies, ranging from 0.08–3.6% per year [2]. The 
mortality was initially overestimated because it was based on studies at tertiary 
referral centres which predominantly included high-risk patients. Recent stud-
ies of community-based patient cohorts have shown that the long-term outcome 
for treated index patients and family members is favourable- annual  
mortality <1% [2].
The prognosis for patients with ARVC depends largely on the severity of 
arrhythmias and ventricular dysfunction. Prior cardiac arrest due to ventricular 
fibrillation and sustained VT are the most important predictors of life-threatening 
arrhythmic events during follow-up. Major risk factors include unexplained syn-
cope, non-sustained VT on ambulatory monitoring or exercise testing, and severe 
systolic dysfunction of the RV, LV or both.
Although intracardiac electrophysiological testing has traditionally been used to 
assess the risk of ventricular arrhythmias, the prognostic value of VT or ventricu-
lar fibrillation induced by programmed ventricular stimulation in patients with 
asymptomatic ARVC remains unclear [2].
10. Management
The aims of clinical management of ARVC are to reduce the risk of sudden 
cardiac death and improve the quality of life by alleviating arrhythmic and heart 
failure symptoms. Restriction from intense sports activity (physical exercise may 
aggravate mechanical uncoupling of myocytes) is regarded as an important preven-
tive tool for both healthy gene carriers and clinically affected persons in order to 
protect them from the risk of exercise-related malignant arrhythmic events and 
disease development or progression. The available evidence indicates that family 
members with a negative phenotype (either healthy gene carriers or those with an 
unknown genotype) do not need any specific treatment other than sports restric-
tion; however, lifelong clinical assessment with the use of non-invasive tests at least 
every 2 years is warranted because of the age-related penetrance and progressive 
nature of ARVC [2].
Despite limited supportive data, beta-blockers are currently recommended for 
all clinically affected persons, for both prevention of arrhythmias and reduction of 
right ventricular wall stress. In patients with ventricular arrhythmias, antiarrhyth-
mic drugs therapy offers the potential to ameliorate symptoms, although there is no 
proof that it confers protection against sudden cardiac death. Amiodarone, alone or 
in association with beta-blockers, and sotalol are the most effective drugs, combin-
ing the synergistic effects of class III antiarrhythmic properties and beta adrenergic 
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blockade. The potential for serious cumulative toxic effects precludes long-term 
therapy with amiodarone, especially in younger patients [2].
Catheter ablation is a therapeutic option for patients who have episodes of 
sustained, monomorphic ventricular tachycardia. However, it should be regarded 
as a palliative rather than curative therapeutic approach because of the high 
frequency of subsequent recurrences of ventricular tachycardia and the unproven 
efficacy of ablation as a means of preventing sudden cardiac death. The poor 
long-term outcome has been attributed to the progressive nature of ARVC, which 
leads to the development of multiple arrhythmogenic foci over time. The epi-
cardial location of some ventricular tachycardia reentry circuits, which reflects 
the propensity of ARVC lesions to originate and progress from the epicardium, 
may also explain the failure of conventional endocardial mapping and catheter 
ablation. Several studies have shown the feasibility and efficacy of epicardial 
catheter ablation for patients in whom one or more endocardial procedures have 
been unsuccessful [2].
Since surgical isolation of RV free wall (a therapeutic approach previously) 
risks postoperative RV failure, this procedure has been replaced by Implantable 
cardioverter-defibrillator (ICD) placement [1]. Although randomised trials of 
defibrillator therapy have not been performed, data from observational stud-
ies have consistently shown that it is effective and safe. Patients who benefit 
most from defibrillators (ICD) are those who have had an episode of ventricular 
fibrillation or sustained ventricular tachycardia. It remains uncertain whether 
defibrillator therapy is appropriate for primary prevention of sudden cardiac 
death among patients with one or more risk factors and no prior major arrhyth-
mic events [2].
In asymptomatic patients with no risk factors and in healthy gene carriers, there 
is generally no indication for prophylactic defibrillator implantation because of 
the low risk of arrhythmias and the significant risk of device and electrode-related 
complications during long-term follow-up [2]. It has become apparent that defibril-
lators may be inappropriately implanted in patients with a false diagnosis of ARVC 
based on misinterpretation of cardiac MRI studies [2].
Patients in whom right or left heart failure develops are treated with a standard 
pharmacologic therapy, including angiotensin-converting enzyme inhibitors, 
angiotensin II receptor blockers, beta-blockers, and diuretics. Therapy with oral 
anticoagulants is reserved for patients with atrial fibrillation or thromboembolic 
complications. Cardiac transplantation is the ultimate therapy for patients with 
untreatable arrhythmias (e.g. incessant storms of ventricular tachycardia or fibril-
lation) or congestive heart failure that is refractory to pharmacologic and nonphar-
macologic therapies [2].
In patients with late complications of the disease, who develop heart failure 
symptoms or life-threatening and untreatable VT, heart transplantation could be an 
option with good short and long-term survival. Heart transplantation is essentially 
the final therapeutic option for these patients [1].
Current therapeutic approaches to ARVC are palliative and partially alleviate 
symptoms and the risk of sudden cardiac death but do not prevent the development 
or progression of the disease process. A definitive curative treatment will require a 
deeper knowledge of the biologic mechanisms and environmental factors involved 
in the pathogenesis of ARVC. A recent observation concerns a small molecule desig-
nated SB216763, which is an activator of the Wnt signalling pathway. This molecule 
has been shown to prevent or reverse phenotypic manifestations of ARVC induced 
by overexpression of defective plakoglobin in a zebrafish model, as well as in rat 
cardiac myocytes. Although this drug is of interest as a potential mechanism-based 
therapy of ARVC, it has not yet been studied in humans [2].
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11. Conclusion
ARVC is a progressive disease with life-threatening complications, which 
constitute a clinical diagnostic challenge for physicians, given the different geno-
type and phenotypic variations and the wide ranges of clinical manifestations. 
The main challenges to improve the risk stratification for better identification of 
high risk patients of SCD and heart failure, most benefit from early intervention 
with lifestyle changes, restriction of physical activity, antiarrhythmic drugs, ICD 
placement, new ablation approaches with simultaneous endocardial and epicardial 
ablation and, if necessary, heart transplantation. These interventions are available 
and life saving, with the potential to change the natural history of the disease by 
offering a good quality and better life expectancy [1].
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Abbreviations
ARVC Arrhythmogenic right ventricular cardiomyopathy
ARVC/D Arrhythmogenic right ventricular cardiomyopathy/dysplasia
ICD Implantable cardioverter-defibrillator
LBBB Left bundle branch block
LV Left ventricle
MRI Magnetic Resonance Imaging
PKP2 Plakophilin 2
RV Right ventricle
RVOT Right ventricle outflow tract
SCD Sudden cardiac death
TGF Transforming growth factor
VT Ventricular tachycardia
WHO World Health Organisation
ARVC at a quick glance
• Arrythmogenic right ventricular cardiomyopathy (ARVC) is a genetic form of cardiomyopathy causing 
fibro-fatty replacement of the myocardium.
• Transmission is usually autosomal dominant, with a male to female preponderance.
• The desmoplakin gene (DSP), the first desmosomal protein gene to be associated with a major form of 
the disease.
• ARVC is a myocyte adhesion disorder.
• ARVC is currently the second most common cause of SCD in the young population.
• Pathophysiology includes myocardial atrophy, fibrofatty replacement, and chamber dilatation.
• ARVC presents a diagnostic challenge- 2010 revised task force criteria for ARVC, ECG, echocardiogram, 
cardiac MRI, myocardial biopsy, family screening and risk stratification being the cornerstones.
• Therapeutic options are based on preventing life-threatening arrhythmia– both primary and secondary 
prevention – starting from ICD and radiofrequency ablation to heart transplantation in patients with late 
complications.




Royal Preston Hospital, United Kingdom
*Address all correspondence to: sukanyaghosh18@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Arrhythmogenic Right Ventricular Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.96855
References
[1] Jorge Romero; et al.“Arrhythmogenic 
right ventricular cardiomyopathy 
ARVC/D: A systemic literature review”. 
Clinical Medicine Insights: Cardiology 
Libertas Academica 2013; 7(7):97-114.
[2] Domenico Corrado; et 
al.“Arrhythmogenic Right Ventricular 
Cardiomyopathy” The New England 
Journal of Medicine 2017; 376:61-72.
[3] Marcus FI;et al. “Genetics of 
arrythmogenic right ventricular 
cardiomyopathy: a practical guide for 
physicians.” J Am Coll Cardiology 2013; 
61:1945-8.
[4] Lancisi GM: “De Motu Cordis et 
Aneurysmatibus.” Naples. 1736
[5] Dalla Volta S,et al. “‘Auricularization’ 
of right ventricular pressure curve.” Am 
Heart J. 1961, 61: 25-33.
[6] Thiene G,et al.“Arrhythmogenic right 
ventricular cardiomyopathy/dysplasia.” 
Orphanet J Rare Dis 2, 45 (2007).
[7] MacRae CA, et al. “Arrhythmogenic 
right ventricular cardiomyopathy: moving 
toward mechanism.” J Clin Invest. 2006 
Jul;116(7):1825-8.
[8] Rampazzo A,et al. “A new locus for 
arrhythmogenic right ventricular 
cardiomyopathy (ARVD2) maps to 
chromosome 1q42-q43.” Hum Mol Genet. 
1995;4(11):2151-4.
[9] Carol G et al. “ Arrhythmogenic right 
ventricular cardiomyopathy” J Am Coll 
Cardiol. 2001 Dec, 38 (7) 1773-1781.
